As an anti-IL6R antibody, tocilizumab has been FDA-approved for the treatment of rheumatic disease and has recently been evaluated for the treatment of solid tumors in clinical trials.42–44 Our study reconfirmed that targeting IL6R could reduce NSCLC-BM.45 Considering the direct role of tocilizumab on lung cancer cells, we explored the effect of tocilizumab in inhibiting brain metastases following microglial depletion with PLX5622. This evidence concerns the gene IL6R and rheumatic disorder.